Outcomes by baseline liver function in patients with unresectable hepatocellular carcinoma treated with tremelimumab and durvalumab in the phase III HIMALAYA study Meeting Abstract
| Authors: | Vogel, A.; Chan, S. L.; Furuse, J.; Tak, W. Y.; Masi, G.; Varela, M.; Kim, J. H.; Tanasanvimon, S.; Reig Monzon, M. E.; Dayyani, F.; Makowsky, M.; Marcovitz, M.; Negro, A.; Abou-Alfa, G. K. |
| Abstract Title: | Outcomes by baseline liver function in patients with unresectable hepatocellular carcinoma treated with tremelimumab and durvalumab in the phase III HIMALAYA study |
| Meeting Title: | ESMO Asia Congress 2022 |
| Journal Title: | Annals of Oncology |
| Volume: | 33 |
| Issue: | Suppl. 9 |
| Meeting Dates: | 2022 Dec 2-4 |
| Meeting Location: | Singapore |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2022-11-01 |
| Start Page: | S1463 |
| End Page: | S1464 |
| Language: | English |
| ACCESSION: | WOS:000897943700081 |
| DOI: | 10.1016/j.annonc.2022.10.115 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 79P -- Source: Wos |
